

RIBOMIC Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference

TOKYO, December 23, 2021 - RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TYO:4591), today announced that Yoshikazu Nakamura Ph.D., President and CEO, will give a corporate presentation at the 40th J.P. Morgan Healthcare Conference. The date/time and the other details are as follows:

Date and time: January 10, 2022, 10:00 am -10:25 am (EST, U.S.A.)
※JST January 11, 2022, 0:00 am -0:25 am
Method: Virtual webcast
Meeting URLs: https://jpmorgan.metameetings.net/events/healthcare22/sessions/40316-ribomic-inc/webcast?gpu_only=true&kiosk=true

Presentation materials will be available on our website after the presentation is completed.

ABOUT J.P. Morgan Healthcare Conference

The conference is one of the largest annual meetings in the life sciences industry, where thousands of investors and executives from around the world (typically) gather in San Francisco to announce the latest technological innovations to search for the next partner or investor.

Due to the outbreak of COVID-19, the 40th Annual Health Care Conference will take place virtually. In this conference, only a few Japanese bio-venture companies make presentations every year, and RIBOMIC has been giving presentations for the third consecutive year.

ABOUT RIBOMIC

RIBOMIC is a clinical stage bio-pharmaceutical company specializing in the discovery and development of aptamer therapeutics, which is one type of nucleic acid medicine, a field with much potential for the development of next-generation drugs. The RiboART system, the company's core drug discovery platform, can be used for the discovery of many types of aptamer drugs. RIBOMIC is dedicated to the discovery and development of drugs that target the broad field of unmet medical needs, which encompasses eye disorders, rare disease of short stature in children and many other diseases.

See RIBOMIC website for more information.

<https://www.ribomic.com/eng/>

Forward-Looking Statements

This announcement contains forward-looking statements relating to current plans, estimates, strategies, belief and the future performance of Company. These statements are based on Company's current expectations in light of the information and assumptions currently available so that Company does not promise the realization and these expectations may differ materially from those discussed in the forward-looking statements. These factors include, but not limited to, i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, ii) currency exchange rate fluctuations, iii) claims and concerns on the product safety and efficacy, iv) completion and discontinuation of clinical trials, v) infringement of Company's intellectual property rights by third parties.

Information on pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

"RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.

Contacts for inquiries or additional information:
RIBOMIC Inc.
ir.inquiry@ribomic.com